Cocrystal Pharma (NASDAQ:COCP) versus Aytu BioPharma (NASDAQ:AYTU) Head to Head Review

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Aytu BioPharma (NASDAQ:AYTU – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Volatility and Risk

Cocrystal Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Insider and Institutional Ownership

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 6.1% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Cocrystal Pharma and Aytu BioPharma”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cocrystal Pharma $330,000.00 57.61 -$8.83 million ($0.76) -1.30
Aytu BioPharma $57.57 million 0.35 -$14.25 million ($1.66) -1.11

Cocrystal Pharma has higher earnings, but lower revenue than Aytu BioPharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Cocrystal Pharma and Aytu BioPharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cocrystal Pharma 1 0 1 0 2.00
Aytu BioPharma 2 0 2 0 2.00

Aytu BioPharma has a consensus target price of $14.50, suggesting a potential upside of 690.19%. Given Aytu BioPharma’s higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than Cocrystal Pharma.

Profitability

This table compares Cocrystal Pharma and Aytu BioPharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cocrystal Pharma N/A -207.47% -123.33%
Aytu BioPharma -24.76% -56.54% -13.14%

Summary

Aytu BioPharma beats Cocrystal Pharma on 7 of the 13 factors compared between the two stocks.

About Cocrystal Pharma

(Get Free Report)

Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.

About Aytu BioPharma

(Get Free Report)

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.